In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin
详细信息 查看全文
- 作者：Matteo Santoroa ; 1 ; Walter Maetzlerb ; c ; 1 ; Petros Stathakosa ; Heather L. Martina ; Markus A. Hobertb ; c ; Tim W. Rattayb ; c ; Thomas Gasserb ; c ; John V. Forrestera ; d ; e ; Daniela Bergb ; c ; Kevin J. Traceyf ; Gernot Riedela ; Peter Teismanna ; pteismann@gmx.de" class="auth_mail" title="E-mail the corresponding author
- 关键词：COX ; cyclooxygenase ; CSF ; Cerebrospinal fluid ; DOPAC ; 3 ; 4-Dihydroxyphenylacetic acid ; GFAP ; glial fibrillary acidic protein ; H&Y ; Hoehn & Yahr ; HMGB1 ; high-mobility group box 1 ; HVA ; homovanillic acid ; MPP+ ; ; 1-methyl-4-phenylpyridinium ; MPTP ; 1-methyl-4-phenyl-1 ; 2 ; 3 ; 6-tetrahydropyridine ; OD ; optical density ; PD ; Parkinson's disease ; RAGE ; receptor for advanced glycation endproducts ; SNpc ; substantia nigra pars compacta ; TH ; tyrosine-hydroxylase ; TNF-α ; tumour necrosis factor-alpha ; Wt ; wil
- 刊名：Neurobiology of Disease
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：91
- 期：Complete
- 页码：59-68
- 全文大小：1910 K
文摘
- •
HMGB1 is up-regulated in Parkinson's disease.
- •
HMGB1 is translocalized into the cytoplasm after MPTP.
- •
Inhibition of HMGB1 protects against MPTP-toxicity.
- •
Translocalization of HMGB1 is reduced after inhibition a neutralizing antibody or glycyrrhizin.